Sidney Kimmel Center for Prostate and Urologic Cancers: Related News

On Our Blog

Prostate Cancer Organoids Provide New Tool for Evaluating Therapies

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

September 4, 2014
Brett Carver
Memorial Sloan Kettering Researchers Discover How Prostate Cancer Disease Pathways Regulate Each Other

Memorial Sloan Kettering researchers have discovered that the AR and PI3K disease pathways regulate each other through reciprocal negative feedback.

July 1, 2011
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011
New Program Can Help Cancer Patients Preserve Fertility

Memorial Sloan Kettering has established a fertility preservation program within the Center’s Cancer Survivorship Initiative to provide information and resources to clinicians to help them initiate discussions with patients about fertility preservation.

June 1, 2010

Related Media Coverage

Drug Shown To Significantly Improve Survival In Men With Metastatic Prostate Cancer While Exploring A Potential Biomarker To Measure Treatment Response

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

June 4, 2011
Drug Shown to Improve Overall Survival in Patients with Metastatic Prostate Cancer

An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.

May 25, 2011
Blood Test Given Earlier Than Recommended Predicts Long-Term Risk of Death from Prostate Cancer and Suggests Annual PSA Testing for Most Men is Unnecessary

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

May 19, 2011